25 March 2020
Botanix announces top line BTX 1204 atopic dermatitis data
• BTX 1204 did not achieve statistical significance in the primary and secondary endpoints in its
Phase 2 atopic dermatitis study
• Botanix will be finalising a comprehensive review of the study data and will provide an update
on the BTX 1204 program and its broader dermatology platform
Philadelphia PA and Sydney Australia, 25 March 2020: Clinical stage synthetic cannabinoid company
Botanix Pharmaceuticals Limited (ASX:BOT, “Botanix” or “the Company”) today announced that BTX
1204 did not meet the primary endpoint in its Phase 2 study evaluating the safety and efficacy in
patients with moderate atopic dermatitis (“1204 Study”).
Sad
- Forums
- ASX - By Stock
- Ann: Antimicrobial Platform Update and Launch of BTX 1801 Study
25 March 2020Botanix announces top line BTX 1204 atopic...
Featured News
Add BOT (ASX) to my watchlist
|
|||||
Last
34.0¢ |
Change
0.020(6.25%) |
Mkt cap ! $615.4M |
Open | High | Low | Value | Volume |
32.0¢ | 34.0¢ | 32.0¢ | $1.776M | 5.339M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 118187 | 33.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
34.0¢ | 698385 | 8 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 118187 | 0.335 |
5 | 47944 | 0.330 |
10 | 655576 | 0.325 |
24 | 1211890 | 0.320 |
12 | 845958 | 0.315 |
Price($) | Vol. | No. |
---|---|---|
0.340 | 698385 | 8 |
0.345 | 214401 | 6 |
0.350 | 265310 | 8 |
0.355 | 133069 | 6 |
0.360 | 429541 | 11 |
Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
Featured News
BOT (ASX) Chart |